Medizone International, Inc. (OTCBB: MZEI) (http://medizoneint.com)
While MRSA is the ’superbug’ obtaining the most press recently —it is important to remember this is not the only ’superbug’ AsepticSure™ kills and not the only ’superbug’ hospital administrators worry about.
Medicare will begin implementing cost controls on health care providers, mostly through penalties and incentives and reduce payments for hospital-acquired infections or preventable hospital admissions. Hospitals are scrambling for solutions.
Pseudomonas Aeruginous is also a big problem for hospitals and responsible for as many as one in ten hospital acquired infections. Disinfectants commonly used in homes and medical facilities can boost the resistance of some bacteria to life-saving antibiotics, according to findings published in the journal Microbiology which also pointed to the possibility that other drug-resistant hospital killers — such as MRSA (methicillin-resistant Staphylococcus aureus) and C-diff (Clostridium difficile) — could spread and build up immunity to antibiotics in the same way.
The findings shed light on how Pseudomonas aeruginosa spreads.
P. aeruginosa is a an “opportunistic” bacteria that attacks people with weakened immune systems.
It typically infects the pulmonary and urinary tracts, as well as burns and puncture wounds.
In laboratory experiments, researchers showed that the bug can rapidly mutate, building resistance to progressively higher doses of a disinfectant known as BSK, or benzalkonium chloride.
Safe for humans, BSK is widely-used in cleaning and disinfecting products to kill bacteria, fungi and algae.
The DNA-altered bacteria were able withstand concentrations of BSK up to 400 times greater than the non-mutated strain.
More critically, they also developed a resistance to an antibiotic, ciprofloxacin, even though they had never been exposed to the drug.
Ciprofloxacin is a front-line medication in the fight against several bacterial infections, and is also the drug of last-resort against the deadly disease anthrax.
The disinfectant-resistant strain of P. aeruginosa built up immunity against ciprofloxacin up to ten times more effectively than did the baseline bacteria, the study reported.
In further experiments, Fleming and colleagues put the two strains together in an environment containing a diluted dose of disinfectant, such as might be found in a hospital or home.
The mutated bugs were “highly competitive” with the non-mutated ones, noted the report’s author, “They outgrew the so-called ’sensitive’ strains so rapidly it was hard to believe.”
“That means that we have a problem — disinfectant may proliferate antibiotic resistance,” he added.
The AsepticSure™ system is capable of decontamination to the previously unobtainable 6 log standard on all hospital surfaces, hard or soft.
Medizone International has demonstrated successful decontamination by AsepticSure™ to the 6 log standard or greater has been demonstrated with:
- C.difficile
- E coli
- Pseudomonas aeruginous
- MRSA
- VRE
- Bacillius subtilis
- Hospitals
- Sports training facilities
- Schools
- Critical infrastructure
Contact: Medizone International, Inc. (OTCBB: MZEI)
(See Medizone International Video)
http://www.medizoneint.com
Telephone: 415-868-0300
Fax: 415-868-2344
Address:
Post Office Box 742
Stinson Beach, CA 94970
This release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.
Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
